Most know that I have been a supporter and also very hopeful about allogeneic cell company Athersys. I've written several articles over the years with my best work
. Athersys failed in ulcerative colitis (so far) but the big opportunity is the stroke trial.., smartly designed, compelling science and fully enrolled. Results are due by early April. Here is a recent
by Gil van Bokkelen that is worth watching. I'm curious how many diehard Cytori investors here are also taking a shot with Athersys. The company has been managed extremely will in comparison the terribly managed Cytori over the years.
I have a small position. They got killed with the colitus trial but I think the management is solid. I always thought a merger of some sort with Cytori would have been a great deal. Guess CC et al didn't want to move to Cleveland!
Athersys to discuss the recently announced collaboration with Chugai Pharmaceutical Co., Ltd at Asia meeting in late March regarding the development of its proprietary MultiStem(R) cell therapy for ischemic stroke in Japan, and to explore other partnering opportunities with leading pharmaceutical and biotech companies.
I follow both companies quite closely. Thank you for your research contributions to both.
I currently have equal share positions in Athersys and Cytori with a low per share cost basis in both companies.
I am quite excited about Athersys and nervous through P2 stroke results. They are likely to have the first approved and reimbursable stem cell therapy under Japan's new rules and will gather a lot of attention. They have been mindful of shareholders and partnerships. With positive P2 stroke results this company could grow quite quickly. I am trying to decide whether to let my entire position ride through Stroke results or sell some in early April to protect my initial costs.
Like others I have been up and down and in and out of Cytori over the last six years. Overall, I have lost money on Cytori but for as much as I have invested I have been fortunate to have avoided the major drops. It is such a shame that we wasted so much resources chasing soft tissue and fighting the FDA. Company leaders simply did not understand the economics, needed regulatory approvals and motivations of some of their approaches. I trusted management to know the markets and needs of potential partners better. So, I got burned like everyone else.
I am excited about recent events at Cytori and believe we still have a future. Cytori seems to have a solid relationship with the US FDA and BARDA. I am really excited about the next generation Cellution where we could monitor the application and the quality of the machine output.
I think this capability increases support from the FDA and sets Cytori apart from being an equipment vendor to a becoming a health care specialist.
I have recently added to my position after it cleared the $1.00 de-listing hurdle.
The following user(s) said Thank You: DOV, fatboy, Wall Street Titan